Septa Pharmaceuticals Inc. adquiere CeeNU® (Lomustina) de Bristol Myers Squibb, Canadá

CeeNU®Positive

AI Analysis

Summary

Septa Pharmaceuticals Inc. acquired CeeNU® (Lomustina) from Bristol Myers Squibb Canada effective June 29, 2026, expanding its portfolio in the Canadian healthcare sector.

Outcome Details

Septa Pharmaceuticals acquired CeeNU® (Lomustina) from Bristol Myers Squibb, Canada, effective June 29, 2026

Importance:4/10

Sentiment:

0.30

acquisitioncanadaproduct acquisition

Related Companies

$BMY

Read the original article

Published by PR Newswire Pharma on July 15, 2026 11:00 AM

Read Original